Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC A comprehensive analysis | Caris Life Sciences
Home / Research / Publications / Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC A comprehensive analysis

Publications

Investigating the clinical and molecular characteristics of class II and III BRAF mutations and their response to anti-EGFR therapy in MSS CRC A comprehensive analysis

Significance and Background

  • BRAF mutations represent a highly heterogeneous group of molecular alterations seen in colorectal cancer (CRC).
  • Class I BRAF mutation (V600) render aggressive biology to CRC and poor response to EGFR blockade therapy.
  • Currently there are limited data on clinical and molecular features of class II and III BRAF mutations and their response to EGFR blockade therapy.
  • In this large comprehensive cohort study, we investigated the clinical and molecular characteristics of BRAF mutation classes and their impact on clinical outcomes in a large cohort of patients with mismatch proficient-microsatellite stable CRC.

Download Publication
Learn More
Name(Required)